Default company panoramic image
Logo

Traverse Biosciences, Inc.

TRB-N0224 is envisioned as the first FDA-approved, once-daily edible prescription medication for the prevention and control of canine periodontal disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Stony Brook, NY, USA
  • Currency USD
  • Founded June 2013
  • Employees 1
  • Incorporation Type C-corp
  • Website traversebiosciences.com

Company Summary

Traverse Biosciences is commercializing a proprietary pipeline of drug candidates to treat inflammatory and age-related diseases affecting humans and animals. Our lead compound, TRB-N0224, is envisioned as the first FDA-approved, once-daily edible prescription medication for the prevention of canine periodontal disease, with annual sales expected to exceed $100M in the US alone.

Team

  • Mr. Scaduto is currently an external BioEntrepreneur-In-Residence designated by the philanthropic Advisory Board of the Center for Biotechnology at Stony Brook University. In this capacity, he is charged with the identification, evaluation and commercialization of promising biomedical technologies through new venture creation. Email: [email protected]

  • Default avatar
    Lorne Golub, DMD, MD (Honorary)
    Scientific Advisor

    Distinguished Professor, School of Dental Medicine, Stony Brook University. Co-Inventor of Periostat(R) and Oracea(R), developed by Collagenix Pharmaceuticals, which was acquired by Galderma in 2008 for $420M.

  • Default avatar
    Francis Johnson, Ph.D.
    Scientific Advisor

    President, Chem-Master International, Inc.; Professor, Department of Pharmacological Sciences and Department of Chemistry, Stony Brook University.

Advisors

  • Default avatar
    Nixon Peabody, LLP
    Lawyer
    Unconfirmed